Prognostic factors in angioimmunoblastic lymphadenopathy

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Angioimmunoblastic lymphadenopathy (AIL) is a rare T-cell lymphoproliferative disorder.
• Identifying prognostic factors is crucial for optimizing patient management and therapeutic strategies.

Purpose of the Study:

• To prospectively identify prognostic factors in patients diagnosed with angioimmunoblastic lymphadenopathy (AIL).

Main Methods:

• Prospective follow-up of 30 directly diagnosed AIL patients for over 42 months.
• Analysis of demographic, clinical, laboratory findings, and patient outcomes.
• Statistical evaluation to determine factors associated with survival.

Main Results:

• Median survival was 24 months.
• Localized adenopathies and achieving remission were associated with longer survival (P=0.01, P<0.0001).
• Drug exposure, rash, lymph node eosinophilia, and elevated serum LDH correlated with shorter survival (P=0.02-0.03).

Conclusions:

• Localized adenopathy and remission are favorable prognostic indicators in AIL.
• Drug exposure, rash, and elevated LDH suggest a poorer prognosis.
• Multicenter prospective studies are needed to further define AIL and optimize treatment.